U.S. Food and Drug Administration


Why We're Still Avoiding WMT Stock Despite Today's Major Acquisition News

The WMT stock price has gained nearly 1% today on some big acquisition news.

Reports say that Wal-Mart plans to acquire online retailer

Despite the news, there's one reason we're avoiding Wal-Mart stock in 2016...


Jose Cuervo IPO: 10 Facts We Know So Far

The Jose Cuervo IPO was just announced this morning.

The tequila company is planning an initial public offering of up to $1 billion.

And we've developed a three-step strategy for investing in the company once it goes public...


The USFD IPO Price Is Set – Here's a Breakdown of the Deal

The second-biggest IPO of the year just hit the market.

U.S. Foods stock started trading this morning after the USFD IPO price was set at $23.

With an immediate gain of more than 5% today, investors want to know if they should buy shares today...


A New Double-Digit Opportunity That Analysts Are Missing – Again

There's an old joke on Wall Street: God invented analysts to make weather forecasters look good.

Meant as a tongue-in-cheek poke at the complexity of financial markets, it's unfortunately all too true.

Most conventional analysts are often myopically focused and very close – too close – to the companies they cover. More often than not, they fail to see critical product developments, miss industry-specific competitor information, and appear blind to basic common-sense developments that could materially affect stock prices.

Worse, they're often bullish when they should be bearish and bearish when they should be bullish.

Like lemmings, they'd rather go off the cliff together. The fact that they take millions of unsuspecting investors with them is an afterthought.

That's bad if you depend on them – but great if you know how to pounce on the openings they inadvertently create.

We've talked about this several times over the past year with great success. Each time, you've had the opportunity to rack up double-digit returns on analysts' "mistakes."

This time around, though, I think the potential may be even bigger...


"Pharma Bro" Martin Shkreli Really Upped His Weirdo Villain Game This Week

"Pharma Bro" Martin Shkreli, the CEO of Turing Pharmaceuticals, has been America's favorite corporate villain lately.

On Sept. 21, 2015, public ire for the young biopharma exec surfaced after he purchased the rights to the drug Daraprim and skyrocketed the price to $750 overnight.

Public relations in the weeks since for the young exec have only gotten worse...